NEW YORK, Sept. 6, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blueprint Medicines Corporation BPMC based on allegations that Blueprint Medicines may have disclosed materially misleading business information to the investing public.

SO WHAT: If you have purchased Blueprint Medicines securities, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=8186 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action.

WHAT IS THIS ABOUT: On August 17, 2022, prior to trading hours, Blueprint Medicines announced top-line results from Enrollment Part 2 of its PIONEER clinical trial of AYVAKIT^® (avapritinib) in patients with non-advanced systemic mastocytosis (SM). The results showed a worsening of the absolute symptom score improvement from 15.6 points in this latest study versus 19.7 in phase 1.

As a result of this news, Blueprint Medicine’s stock price fell $7.38 per share, or 10%, due to unusually high trading volume, to close at $61.17 per share on August 17, 2022.

WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Frequently, companies that issue notices do not have comparable experience, resources, or meaningful recognition from peers. Be wise in choosing a lawyer. The Rosen law firm represents investors worldwide and focuses its practice on securities class actions and shareholder derivatives litigation. Rosen Law Firm has achieved the largest-ever settlement of a securities class action lawsuit against a Chinese company. Rosen law firm was founded by…